Skyclarys (omaveloxolone) - Biogen
Differentiated LUHMES Cells as a Model to Investigate Neurotropic Arboviruses and Evaluate Host-Directed Therapeutics. (PubMed, Microorganisms) - Sep 27, 2026 - "We also demonstrated how the model may be applied to evaluate potential therapeutic options using an FDA-approved small molecule, Omaveloxolone. Finally, we analyzed host cell responses to infection and treatment using gene expression and phospho-signaling analyses. These findings highlight the value of this model to interpret the pathogenic mechanisms of neurotropic viral infections and evaluate potential therapeutic intervention strategies in a clinically relevant in vitro human neuronal model." 
Journal • CNS Disorders • Dengue Fever • Infectious Disease
http://www.ncbi.nlm.nih.gov/pubmed/42795526
 
Aarthi Narayanan; Alison Gomeiz; Dylan Valerio Scarton; Elsa Ronzier; Jonathan Ontivero Sanchez; Lorreta Aboagyewa Opoku; Maame Konadu; Mariaelena Pierobon; Michael D Barrera; Rémi Veneziano; Shannon D Walls; Stephanie V Trefry
 
Sep 27, 2026
 
Prev Next